This acquisition aligns with Danone’s “Renew” strategy, launched in 2022 to rejuvenate its health-driven product lines and accelerate scientific innovation in response to consumer demand. By integrating TAC’s research-based biotic into its portfolio, Danone positions itself at the forefront of microbiome nutrition, a rapidly growing sector that includes dairy-based probiotic and postbiotic offerings.

The MucT™ strain distinguishes itself by being pasteurized rather than live, ensuring stability, longer shelf life, and easier integration into various products — a significant advantage for dairy manufacturers seeking scalable gut-health solutions. Notably, MucT™ was the first next-generation bacterium to receive European Food Safety Authority approval in 2021, reinforcing its regulatory and commercial readiness.

For the international dairy sector, the buyout offers strategic opportunities to harness microbiome science in product development, strengthening value-added dairy and functional nutrition segments. Leveraging TAC’s strain, Danone can enhance its high-growth dairy and plant-based brands by infusing them with clinically backed health benefits.